Pembrolizumab biosimilar (Chong Kun Dang Pharmaceutical)

帕博利珠单抗生物类似药 (Chong Kun Dang Pharmaceutical)

Report date: 2025/02/13 11:06:53

Base Information

Drug NamePembrolizumab biosimilar (Chong Kun Dang Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFavorex Ptd Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChong Kun Dang Pharmaceutical Corp
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A